首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >How a single inversion of configuration leads to a reversal of the binding mode: proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands.
【24h】

How a single inversion of configuration leads to a reversal of the binding mode: proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands.

机译:构型的一次反转如何导致结合模式的逆转:CCK2配体在其受体中的新型排列的提议,以及对拟肽或非肽CCK2配体的发展的贡献。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The implication of CCK(2) receptors in crucial physiological functions has driven the search for synthetic ligands of this receptor. A notable rationale starting from CCK-4 (minimal endogenous CCK(2) agonist), the 'dipeptoid' strategy, led to potent CCK(2) antagonists exemplified by CI-988. However, careful examination of the literature enlightened several incompatibilities between the proposed recognition mode of the receptor by such compounds (or peptide analogues) and experimental data. Thus, we hypothesised that CCK(2) 'dipeptoid' antagonists bind the receptor in a mode opposite to that previously suggested. The reexamination of numerous published data, supported by the characterisation of new 'hybrid' compounds, brought out strong evidence that this 'reverse' mode truly characterises CCK(2) 'dipeptoid' antagonists. These findings renew the perspectives of further chemical development of CCK(2) ligands, e.g. non-peptidic agonists.
机译:CCK(2)受体在关键的生理功能中的含义驱动了该受体的合成配体的搜索。从CCK-4(最小的内源性CCK(2)激动剂)开始的显着原理是“二肽”策略,导致了以CI-988为例的强效CCK(2)拮抗剂。但是,对文献的仔细检查发现,这类化合物(或肽类似物)对受体的识别模式与实验数据之间存在一些不兼容之处。因此,我们假设CCK(2)'depteptoid'拮抗剂以与先前建议的相反的方式结合受体。对新发表的“混合”化合物进行表征的大量公开数据的重新检验,提供了强有力的证据,表明这种“逆向”模式真正表征了CCK(2)“二肽”拮抗剂。这些发现为CCK(2)配体的进一步化学开发提供了新的视角。非肽激动剂。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号